Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1902 1
1919 1
1946 1
1947 1
1948 1
1949 1
1961 1
1965 1
1966 1
1976 2
1977 1
1983 3
1984 3
1987 3
1988 2
1989 3
1990 3
1991 2
1992 8
1993 5
1994 4
1995 6
1996 1
1997 6
1998 5
1999 10
2000 3
2001 4
2002 7
2003 5
2004 10
2005 7
2006 6
2007 11
2008 9
2009 3
2010 7
2011 9
2012 10
2013 14
2014 15
2015 23
2016 24
2017 31
2018 35
2019 20
2020 36
2021 34
2022 43
2023 25
2024 23
2025 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

478 results

Results by year

Filters applied: . Clear all
Page 1
Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial.
Dark P, Hossain A, McAuley DF, Brealey D, Carlson G, Clayton JC, Felton TW, Ghuman BK, Gordon AC, Hellyer TP, Lone NI, Manazar U, Richards G, McCullagh IJ, McMullan R, McNamee JJ, McNeil HC, Mouncey PR, Naisbitt MJ, Parker RJ, Poole RL, Rostron AJ, Singer M, Stevenson MD, Walsh TS, Welters ID, Whitehouse T, Whiteley S, Wilson P, Young KK, Perkins GD, Lall R; ADAPT-Sepsis Collaborators. Dark P, et al. JAMA. 2025 Feb 25;333(8):682-693. doi: 10.1001/jama.2024.26458. JAMA. 2025. PMID: 39652885 Free PMC article. Clinical Trial.
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, Adas MA, Atzeni F, Ng KKH, Rutherford AI, Norton S, Cope AP, Galloway JB. Russell MD, et al. Among authors: cope ap. Ann Rheum Dis. 2023 Aug;82(8):1059-1067. doi: 10.1136/ard-2023-224049. Epub 2023 May 29. Ann Rheum Dis. 2023. PMID: 37247942 Free PMC article.
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, Shah RC, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Johnston CI, Ryan J, Radziszewska B, Jelinek M, Malik M, Eaton CB, Brauer D, Cloud G, Wood EM, Mahady SE, Satterfield S, Grimm R, Murray AM; ASPREE Investigator Group. McNeil JJ, et al. N Engl J Med. 2018 Oct 18;379(16):1509-1518. doi: 10.1056/NEJMoa1805819. Epub 2018 Sep 16. N Engl J Med. 2018. PMID: 30221597 Free PMC article. Clinical Trial.
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T. Kostine M, et al. Among authors: cope ap. Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23. Ann Rheum Dis. 2021. PMID: 32327425 Free PMC article.
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
Cope AP, Jasenecova M, Vasconcelos JC, Filer A, Raza K, Qureshi S, D'Agostino MA, McInnes IB, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga T, Toes R, Georgiou E, Kelly J, Murphy C, Prevost AT; APIPPRA study investigators. Cope AP, et al. Lancet. 2024 Mar 2;403(10429):838-849. doi: 10.1016/S0140-6736(23)02649-1. Epub 2024 Feb 13. Lancet. 2024. PMID: 38364839 Free article. Clinical Trial.
Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation.
Liszewski MK, Kolev M, Le Friec G, Leung M, Bertram PG, Fara AF, Subias M, Pickering MC, Drouet C, Meri S, Arstila TP, Pekkarinen PT, Ma M, Cope A, Reinheckel T, Rodriguez de Cordoba S, Afzali B, Atkinson JP, Kemper C. Liszewski MK, et al. Among authors: cope a. Immunity. 2013 Dec 12;39(6):1143-57. doi: 10.1016/j.immuni.2013.10.018. Epub 2013 Dec 5. Immunity. 2013. PMID: 24315997 Free PMC article.
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Yates M, Mootoo A, Adas M, Bechman K, Rampes S, Patel V, Qureshi S, Cope AP, Norton S, Galloway JB. Yates M, et al. Among authors: cope ap. Arthritis Rheumatol. 2021 May;73(5):779-788. doi: 10.1002/art.41580. Epub 2021 Mar 25. Arthritis Rheumatol. 2021. PMID: 33174384
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.
Hall FC, Cheriyan J, Cope AP, Galloway J, Wilkinson I, Bond S, Norton S, Banham-Hall E, Bayes H, Kostapanos M, Nodale M, Petchey WG, Sheeran T, Underwood J, Jayne DR; TACTIC-R Investigators Group. Hall FC, et al. Among authors: cope ap. Lancet Respir Med. 2023 Dec;11(12):1064-1074. doi: 10.1016/S2213-2600(23)00376-4. Epub 2023 Nov 14. Lancet Respir Med. 2023. PMID: 37977159 Free PMC article. Clinical Trial.
478 results